Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025
CLINUVEL is set to make its debut at the American Academy of Dermatology (AAD) Annual Meeting from March 7-11, 2025, featuring a 4,800-square-foot Pavilion of Photomedicine. The exhibition will showcase the company's innovative melanocortin technology and development program for SCENESSE® (afamelanotide) in treating vitiligo.
The pavilion includes five curated courts highlighting CLINUVEL's innovations, a 360° video installation of patient perspectives, and the 'Derma Hall of Fame' featuring over 60 photomedicine pioneers. The exhibition will also present CLINUVEL's 20-year journey in developing SCENESSE®, the first FDA-approved treatment for erythropoietic protoporphyria (EPP).
The company is currently conducting a global phase III trial (CUV105) evaluating SCENESSE® as an adjunct to narrowband ultraviolet B phototherapy for vitiligo patients aged 12 and above with Fitzpatrick Skin Types III-VI. The AAD Meeting, attracting 20,000 delegates, represents the world's largest gathering of dermatology professionals.
CLINUVEL è pronta a debuttare all'American Academy of Dermatology (AAD) Annual Meeting dal 7 all'11 marzo 2025, presentando un Pavilione di Fotomedicina di 4.800 piedi quadrati. L'esposizione metterà in mostra la tecnologia melanocortin innovativa dell'azienda e il programma di sviluppo per SCENESSE® (afamelanotide) nel trattamento del vitiligine.
Il padiglione include cinque corti curati che evidenziano le innovazioni di CLINUVEL, un'installazione video a 360° con le prospettive dei pazienti e il 'Derma Hall of Fame' con oltre 60 pionieri della fotomedicina. L'esposizione presenterà anche il viaggio di 20 anni di CLINUVEL nello sviluppo di SCENESSE®, il primo trattamento approvato dalla FDA per la protoporfiria eritropoietica (EPP).
L'azienda sta attualmente conducendo una sperimentazione globale di fase III (CUV105) che valuta SCENESSE® come trattamento aggiuntivo alla fototerapia con luce ultravioletta a banda ristretta per pazienti affetti da vitiligine di età pari o superiore a 12 anni con tipi di pelle Fitzpatrick III-VI. L'incontro AAD, che attira 20.000 delegati, rappresenta il più grande raduno di professionisti della dermatologia al mondo.
CLINUVEL está lista para hacer su debut en la Reunión Anual de la Academia Americana de Dermatología (AAD) del 7 al 11 de marzo de 2025, presentando un Pabellón de Fotomedicina de 4,800 pies cuadrados. La exposición mostrará la innovadora tecnología melanocortina de la empresa y el programa de desarrollo para SCENESSE® (afamelanotida) en el tratamiento del vitiligo.
El pabellón incluye cinco espacios curados que destacan las innovaciones de CLINUVEL, una instalación de video de 360° con perspectivas de pacientes y el 'Salón de la Fama Derma' que presenta a más de 60 pioneros de la fotomedicina. La exposición también presentará el viaje de 20 años de CLINUVEL en el desarrollo de SCENESSE®, el primer tratamiento aprobado por la FDA para la protoporfiria eritropoietica (EPP).
La empresa está llevando a cabo actualmente un ensayo clínico global de fase III (CUV105) que evalúa SCENESSE® como un complemento a la fototerapia con luz ultravioleta de banda estrecha para pacientes con vitiligo de 12 años o más con tipos de piel Fitzpatrick III-VI. La reunión de la AAD, que atrae a 20,000 delegados, representa la mayor reunión de profesionales de dermatología en el mundo.
CLINUVEL은 2025년 3월 7일부터 11일까지 열리는 미국 피부과 학회(AAD) 연례 회의에 데뷔할 예정이며, 4,800 평방피트 규모의 광의학관을 선보입니다. 전시회에서는 회사의 혁신적인 멜라노코르틴 기술과 SCENESSE® (아파멜라노타이드)의 백반증 치료 개발 프로그램을 소개할 것입니다.
이 파빌리온에는 CLINUVEL의 혁신을 강조하는 다섯 개의 큐레이션 코트, 환자 관점을 담은 360° 비디오 설치물, 60명 이상의 광의학 선구자를 소개하는 '더마 명예의 전당'이 포함되어 있습니다. 전시회에서는 EPP(적혈구 전구체증)에 대한 FDA 승인 첫 치료제인 SCENESSE®의 20년 개발 여정도 소개될 것입니다.
회사는 현재 12세 이상 Fitzpatrick 피부 유형 III-VI의 백반증 환자를 위한 협력 치료제로서 SCENESSE®를 평가하는 글로벌 3상 시험(CUV105)을 진행하고 있습니다. 20,000명의 대표가 참석하는 AAD 회의는 세계 최대의 피부과 전문의 집합체를 나타냅니다.
CLINUVEL s'apprête à faire ses débuts lors de la Réunion Annuelle de l'Académie Américaine de Dermatologie (AAD) du 7 au 11 mars 2025, présentant un Pavillon de Photomédecine de 4 800 pieds carrés. L'exposition mettra en avant la technologie innovante des mélanocortines de l'entreprise et le programme de développement pour SCENESSE® (afamelanotide) dans le traitement du vitiligo.
Le pavillon comprend cinq espaces soigneusement sélectionnés mettant en lumière les innovations de CLINUVEL, une installation vidéo à 360° offrant des perspectives de patients, et le 'Hall of Fame de la Dermatologie' présentant plus de 60 pionniers de la photomédecine. L'exposition présentera également le parcours de 20 ans de CLINUVEL dans le développement de SCENESSE®, le premier traitement approuvé par la FDA pour la protoporphyrie érythropoïétique (EPP).
L'entreprise mène actuellement un essai clinique mondial de phase III (CUV105) évaluant SCENESSE® comme traitement complémentaire à la photothérapie par ultraviolets à bande étroite pour les patients atteints de vitiligo âgés de 12 ans et plus avec des types de peau Fitzpatrick III-VI. La réunion de l'AAD, attirant 20 000 délégués, représente le plus grand rassemblement de professionnels de la dermatologie au monde.
CLINUVEL wird vom 7. bis 11. März 2025 auf dem Jahrestreffen der American Academy of Dermatology (AAD) debütieren und einen Pavillon für Photomedizin mit einer Fläche von 4.800 Quadratfuß präsentieren. Die Ausstellung wird die innovative Melanocortin-Technologie des Unternehmens und das Entwicklungsprogramm für SCENESSE® (Afamelanotid) zur Behandlung von Vitiligo vorstellen.
Der Pavillon umfasst fünf kuratierte Bereiche, die die Innovationen von CLINUVEL hervorheben, eine 360°-Videoinstallation mit Patientenperspektiven und die 'Derma Hall of Fame', die über 60 Pioniere der Photomedizin präsentiert. Die Ausstellung wird auch die 20-jährige Reise von CLINUVEL bei der Entwicklung von SCENESSE®, der ersten von der FDA zugelassenen Behandlung für erythropoetische Protoporphyrie (EPP), präsentieren.
Das Unternehmen führt derzeit eine globale Phase-III-Studie (CUV105) durch, die SCENESSE® als Ergänzung zur schmalbandigen ultravioletten B-Phototherapie für Vitiligo-Patienten ab 12 Jahren mit Fitzpatrick-Hauttypen III-VI bewertet. Das AAD-Treffen, das 20.000 Delegierte anzieht, ist das weltweit größte Treffen von Dermatologie-Profis.
- FDA-approved SCENESSE® already successful in treating EPP
- Phase III trial ongoing for vitiligo treatment expansion
- Targeting large market opportunity with millions affected by vitiligo
- First systemic therapy for vitiligo without immune suppression
- Phase III trial results still pending
- to specific skin types (III-VI) in current trials
MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, with an immersive exhibition that illuminates the past, present and future of photomedicine.
The 4,800-square-foot Pavilion of Photomedicine has been custom built for CLINUVEL for the AAD Meeting to provide an immersive experience on the history, evolution, and future of photomedicine, including CLINUVEL’s development program with the novel drug SCENESSE® (afamelanotide) to treat vitiligo and work with other melanocortins.
Visitors will travel through five curated courts to experience CLINUVEL’s world of innovation, from the origins of their pioneering melanocortin technology to the ongoing clinical trials that are defining a new approach to treating vitiligo. A 360° video installation explores patients’ perspectives, getting under the skin of what it means to live with visible disorders.
The history and evolution of photomedicine will be on display in the “Derma Hall of Fame”. It pays homage to more than 60 luminaries who have advanced scientific understanding of the interaction between light and human biology. The Pavilion also charts CLINUVEL’s 20-year journey towards developing and commercialising SCENESSE®, the first and only treatment for the rare metabolic disease erythropoietic protoporphyria (EPP).
Vitiligo can inflict profound psychological damage on patients. A series of talks held in the Pavilion gives visitors the opportunity to engage directly with individuals’ experiences. Three conversations with CLINUVEL’s brand ambassadors—each with their own inspiring, challenging story of living with vitiligo—aim to increase understanding and empathy for a condition that often has a complex, personal effect on identity. Additionally, guests will hear about the long-fought path to bringing treatment to those who most need it from two prominent porphyria advocates.
Speakers include Natalie Ambersley, a vitiligo advocate who is also a trustee of the UK-based charity The Vitiligo Society; Briya Fitzgerald, whose own diagnosis drove her to establish a nationwide community called Colorful Connections; Reuben Sam, a model and advocate for vitiligo, as well as Wil McCarthy, award-winning American science author.
“CLINUVEL has established itself as a global leader in understanding the complex relationship between light and skin,” said Dr Linda Teng, CLINUVEL’s Head of North American Operations. “Our FDA-approved melanocortin technology SCENESSE® has helped patients with a rare light-intolerance disorder lead more normal lives and is now showing promise as a treatment for vitiligo, which affects millions of individuals worldwide.”
“The AAD Meeting is the culmination of more than a year of planning and intensive work to expand the reach and depth of our work in vitiligo. We exhibit the world’s first Pavilion of Photomedicine, a momentous undertaking by the team to introduce melanocortins and systemic repigmentation to thousands of new medical professionals.”
The AAD Annual Meeting is the largest annual gathering of dermatologists, researchers, and industry professionals in the world, attracting 20,000 delegates. The Pavilion of Photomedicine is open March 7–9 in Booth 881 and free to enter. AAD 2025 delegates can secure a visit by booking a timeslot in advance.
CLINUVEL’s senior and global clinical teams will be available to discuss their current and future programs, as well as commercial opportunities. It is an unparalleled opportunity to explore the innovative melanocortin technology that places CLINUVEL at the vanguard of photomedicine.
www.clinuvel.com/aad-annual-meeting-2025
Notes to editors:
Accredited journalists at AAD 2025 may book a slot to visit the Pavilion of Photomedicine and arrange interviews via Ms Genevieve Tay.
CLINUVEL is trialling the first systemic therapy in vitiligo to offer extensive repigmentation without suppressing the immune system. The treatment is for patients with more than
About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, repigmentation and acute or life-threatening conditions who lack alternatives.
CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA.
Media Contact:
Ms Genevieve Tay
VP, Communications and Content
mail@clinuvel.com
FAQ
What is the purpose of CLINUVEL's Pavilion of Photomedicine at AAD 2025?
What is the current development status of SCENESSE (CLVLY) for vitiligo treatment?
When and where will CLVLY's Pavilion of Photomedicine be accessible at AAD 2025?
How does CLINUVEL's SCENESSE® (CLVLY) approach vitiligo treatment differently?
